Sai Mirra Innopharm, a pharma player in the domestic and rest of the world (ROW) formulations market, has raised ₹160 crore from Piramal Alternatives, the fund management division of the Piramal Group. The investment, made through Piramal Alternatives’ …

Kalpesh Kikani, managing director, Piramal Alternatives Piramal Alternatives, the fund management unit of Piramal Group, said Tuesday it has invested about Rs 160 crore ($18.8 million) in Chennai-based Saimirra Innopharm Pvt Ltd through its performing …

… and the presence of leading pharmaceutical companies investing heavily in R… creation including TAM expansion, revenue diversification strategies and venturing into new …

… COVID-19 vaccine business. The drugmaker';s revenue is still … , too. The point is, every pharmaceutical company's business ebbs and … it's very well diversified. But aren't most …

… U.S., Viehbacher said. Many pharma companies have a mix of about … is a whole lot more diversified, and that’s really a …

… you close down overnight  Solution: Diversify funding as far as possible … via the Global Fund, the pharmaceutical company Adcock Ingram, and the Australian …

… for stockholders by creating a diversified portfolio of biotech and pharmaceutical … industry in a profitable and diversified manner. Our business model is … with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz …

… could do with some economic diversification and a greater emphasis on … eventually acquired by the global pharmaceutical company GSK for $3 billion. The …

… process of gradual deepening and diversification in the field of … (Supplementary Figure 3), both pharmaceutical companies and academic institutions have contributed … with its involvement as a pharmaceutical company specializing in NOACs research. …

… emphasize that we have a diversified customer base. Our largest monoclonal … of the pharma tariffs, some pharma companies are talking about cutting their … being with a really big pharma company. So that was a very …